{"log_id": 4362727426421465091, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 0.006289, "average": 0.978633, "min": 0.534543}, "location": {"width": 627, "top": 223, "height": 26, "left": 212}, "words": "种族—种族不影响托莫西汀的分布(除PM在高加索人中较普遍这一因素)"}, {"probability": {"variance": 0.00417, "average": 0.975555, "min": 0.792962}, "location": {"width": 177, "top": 261, "height": 27, "left": 212}, "words": "合并躯体疾病的患者"}, {"probability": {"variance": 0.012939, "average": 0.954782, "min": 0.352846}, "location": {"width": 684, "top": 299, "height": 27, "left": 251}, "words": "ADHD患者抽动和并存的 Touretters症状一在随机分组的148名儿科受试者(7-17"}, {"probability": {"variance": 0.002289, "average": 0.982249, "min": 0.719523}, "location": {"width": 747, "top": 344, "height": 26, "left": 212}, "words": "岁)中进行的18周随机、双盲、安慰剂对照研究,这些受试者DSM-IV诊断为ADHD和"}, {"probability": {"variance": 0.000571, "average": 0.97884, "min": 0.930825}, "location": {"width": 190, "top": 389, "height": 24, "left": 213}, "words": "并存的 Touretter s疾病"}, {"probability": {"variance": 0.008354, "average": 0.979264, "min": 0.523283}, "location": {"width": 448, "top": 389, "height": 25, "left": 509}, "words": "疾病:116名受试者;慢性运动性抽动:29名),可变"}, {"probability": {"variance": 0.003059, "average": 0.97861, "min": 0.699041}, "location": {"width": 751, "top": 433, "height": 25, "left": 212}, "words": "剂量范围为0.5-1.5mg/kg/天(平均剂量1.3mg/kg/天)的托莫西汀与安慰剂相当。非劣效分"}, {"probability": {"variance": 0.000381, "average": 0.991192, "min": 0.894432}, "location": {"width": 755, "top": 477, "height": 25, "left": 209}, "words": "析揭示没有加重这些患者的抽动,通过鲁综合抽动严重程度量表总分( YGTSS)确证这些"}, {"probability": {"variance": 0.001095, "average": 0.987406, "min": 0.830039}, "location": {"width": 740, "top": 520, "height": 26, "left": 211}, "words": "患者的抽动情况。进入急性治疗阶段的148名门诊患者中103名患者(69.6%)停止研究"}, {"probability": {"variance": 0.010817, "average": 0.957681, "min": 0.516679}, "location": {"width": 744, "top": 566, "height": 26, "left": 209}, "words": "托莫西汀组(76名患者中的38名.50%)和安慰剂组(72名患者中的45名,62.5%)停"}, {"probability": {"variance": 0.017908, "average": 0.943264, "min": 0.445499}, "location": {"width": 744, "top": 610, "height": 27, "left": 212}, "words": "药的主要原因为缺乏疗效,多数患者于第12周停药、CGI-S24的患者首次访视时符合临"}, {"probability": {"variance": 0.004821, "average": 0.978952, "min": 0.577122}, "location": {"width": 754, "top": 655, "height": 26, "left": 212}, "words": "床未应答标准(CGl-S与基线相同或增加)并进入托莫西汀开放阶段。已有上市后的抽动"}, {"probability": {"variance": 0, "average": 0.999381, "min": 0.999178}, "location": {"width": 42, "top": 703, "height": 22, "left": 209}, "words": "报告"}, {"probability": {"variance": 0.020335, "average": 0.94585, "min": 0.397634}, "location": {"width": 794, "top": 735, "height": 36, "left": 251}, "words": "AHD患者的焦虑和并存的焦虑一在两项上市后、双育、安慰剂对照试验经证A"}, {"probability": {"variance": 0.067868, "average": 0.615327, "min": 0.422009}, "location": {"width": 122, "top": 763, "height": 34, "left": 900}, "words": "深易"}, {"probability": {"variance": 0.000219, "average": 0.991872, "min": 0.942711}, "location": {"width": 468, "top": 786, "height": 29, "left": 211}, "words": "实ADHD患者和焦虑并存的患者服用本品没有加重焦虑"}, {"probability": {"variance": 3e-06, "average": 0.99845, "min": 0.995976}, "location": {"width": 207, "top": 780, "height": 68, "left": 876}, "words": "有公司"}, {"probability": {"variance": 0.006155, "average": 0.978195, "min": 0.602956}, "location": {"width": 610, "top": 829, "height": 30, "left": 252}, "words": "在一项12周双盲、安慰剂对照试验中随机入组年龄为8-17岁的176名患"}, {"probability": {"variance": 0.019823, "average": 0.950674, "min": 0.365712}, "location": {"width": 761, "top": 868, "height": 37, "left": 212}, "words": "者符合ADHD的DSMIⅣ诊断标准以及具有单独焦虑、广泛性焦虑障碍或社交恐惧症"}, {"probability": {"variance": 0.005347, "average": 0.97589, "min": 0.635092}, "location": {"width": 751, "top": 919, "height": 29, "left": 213}, "words": "少一种焦虑症状。2周双盲安慰剂导入期后,本品开始剂量为0.mg/kg/天,增加至目标剂"}, {"probability": {"variance": 0.004559, "average": 0.980123, "min": 0.605468}, "location": {"width": 746, "top": 962, "height": 33, "left": 213}, "words": "量1.2mg/kg天(中位剂量为1.30mg/kg/天+0.29mg/kg天)。托莫西汀没有加重这些患者的"}, {"probability": {"variance": 0.005583, "average": 0.977706, "min": 0.579451}, "location": {"width": 757, "top": 1006, "height": 32, "left": 213}, "words": "焦虑症状,通过儿童焦虑量表(PARS)确证这些患者的焦虑情况。在完成双盲安慰剂导入"}, {"probability": {"variance": 0.007168, "average": 0.974783, "min": 0.579592}, "location": {"width": 406, "top": 1054, "height": 25, "left": 213}, "words": "期的158名患者中,26名(16%)患者停止研究"}, {"probability": {"variance": 0.005931, "average": 0.977608, "min": 0.551435}, "location": {"width": 722, "top": 1093, "height": 32, "left": 252}, "words": "在另外一项16周、双盲、安慰剂对照试验中,入组年龄为18-65岁的442名患者,这"}, {"probability": {"variance": 0.001034, "average": 0.986599, "min": 0.819196}, "location": {"width": 760, "top": 1136, "height": 35, "left": 213}, "words": "些患者符合ADHD的DSM-IV诊断标准以及社交恐惧症(23%患者具有广泛性焦虑障"}, {"probability": {"variance": 0.010294, "average": 0.955923, "min": 0.520469}, "location": {"width": 666, "top": 1182, "height": 31, "left": 214}, "words": "碍)。2周双盲安慰剂导入期后,本品开始剂量为40mg/kg天,增加至目标剂量"}, {"probability": {"variance": 0.001561, "average": 0.982766, "min": 0.802503}, "location": {"width": 759, "top": 1225, "height": 33, "left": 215}, "words": "天(中位剂量为83mgkg天±19.5mg/kg天)托莫西汀没有加重这些患者的焦虑症状,通"}, {"probability": {"variance": 0.000568, "average": 0.989475, "min": 0.872884}, "location": {"width": 760, "top": 1269, "height": 31, "left": 214}, "words": "过社交焦虑量表(LSAS)确证这些患者的焦虑情况。在完成双盲安慰剂导入期的413名患"}, {"probability": {"variance": 0.009893, "average": 0.95609, "min": 0.515377}, "location": {"width": 702, "top": 1312, "height": 31, "left": 214}, "words": "者中,149名:36.1%)患者停止研究。已有上市后焦虑报告一在患有慢性抽动或To"}, {"probability": {"variance": 0.005983, "average": 0.975869, "min": 0.527037}, "location": {"width": 786, "top": 1355, "height": 33, "left": 213}, "words": "综合症的儿童ADHD患者中进行的一项对照研究中,相比安慰剂组,盐酸托莫西汀疗组产"}, {"probability": {"variance": 0.037103, "average": 0.86379, "min": 0.591383}, "location": {"width": 109, "top": 1358, "height": 49, "left": 1002}, "words": "州医约"}, {"probability": {"variance": 0.00615, "average": 0.980767, "min": 0.48671}, "location": {"width": 891, "top": 1396, "height": 35, "left": 214}, "words": "患者的抽动未恶化。在患有抑郁症的青少年ADHD患者中进行的一项对照研究中,相比安有限公司"}, {"probability": {"variance": 0.001154, "average": 0.988195, "min": 0.800217}, "location": {"width": 761, "top": 1418, "height": 60, "left": 214}, "words": "慰剂组,盐酸托莫西汀治疗组患者的抑郁症未恶化。在患有焦虑障碍的ADHD患者"}, {"probability": {"variance": 0, "average": 0.977359, "min": 0.977359}, "location": {"width": 21, "top": 1444, "height": 22, "left": 956}, "words": "项"}, {"probability": {"variance": 0.003101, "average": 0.984822, "min": 0.652183}, "location": {"width": 760, "top": 1486, "height": 34, "left": 215}, "words": "为儿童患者,另一项为成人患者)中进行的两项对照试验中,相比安慰剂组,盐酸托莫西"}, {"probability": {"variance": 0.016673, "average": 0.551952, "min": 0.378834}, "location": {"width": 130, "top": 1557, "height": 49, "left": 623}, "words": "章贸"}, {"probability": {"variance": 0.032772, "average": 0.576223, "min": 0.44153}, "location": {"width": 123, "top": 1542, "height": 39, "left": 935}, "words": "礼账贸"}, {"probability": {"variance": 0.014559, "average": 0.87836, "min": 0.727903}, "location": {"width": 172, "top": 1579, "height": 74, "left": 603}, "words": "有限公司"}, {"probability": {"variance": 0.014953, "average": 0.915361, "min": 0.70573}, "location": {"width": 161, "top": 1575, "height": 45, "left": 914}, "words": "有限公司"}, {"probability": {"variance": 0.059889, "average": 0.784382, "min": 0.441283}, "location": {"width": 101, "top": 1603, "height": 45, "left": 1050}, "words": "谈存档"}], "language": 3}